Literature DB >> 15644187

RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics.

Antonin de Fougerolles1, Muthiah Manoharan, Rachel Meyers, Hans-Peter Vornlocher.   

Abstract

Small interfering RNA (siRNA) mediated inhibition of gene expression has rapidly become a major tool for in vitro analysis of protein function. In vivo gene silencing by siRNAs will play an important role for target validation and is the first step towards the development of siRNA-based therapeutics. This chapter reviews the early and intriguing successes in using siRNAs for in vivo gene silencing. The impact of chemical modification on siRNA efficacy in vitro and the potential for employing such modifications to alter the pharmacokinetic properties of siRNAs is also summarized. A protocol describing siRNA-based gene silencing in tumor models can serve as guide for the design of individual in vivo RNA interference experiments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644187     DOI: 10.1016/S0076-6879(04)92016-2

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  17 in total

1.  Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity.

Authors:  Bryan A Kraynack; Brenda F Baker
Journal:  RNA       Date:  2005-11-21       Impact factor: 4.942

2.  Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA.

Authors:  Katarzyna Sipa; Elzbieta Sochacka; Julia Kazmierczak-Baranska; Maria Maszewska; Magdalena Janicka; Genowefa Nowak; Barbara Nawrot
Journal:  RNA       Date:  2007-06-21       Impact factor: 4.942

3.  Stepwise synthesis of RNA conjugates carrying peptide sequences for RNA interference studies.

Authors:  Anna Aviñó; Sandra M Ocampo; Clara Caminal; José Carlos Perales; Ramon Eritja
Journal:  Mol Divers       Date:  2009-02-03       Impact factor: 2.943

4.  RNA interference with special reference to combating viruses of crustacea.

Authors:  Kathy La Fauce; Leigh Owens
Journal:  Indian J Virol       Date:  2012-08-14

5.  Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum.

Authors:  John A H Hoerter; Nils G Walter
Journal:  RNA       Date:  2007-09-05       Impact factor: 4.942

6.  Fluorescence cross-correlation spectroscopy reveals mechanistic insights into the effect of 2'-O-methyl modified siRNAs in living cells.

Authors:  Thomas Ohrt; Wolfgang Staroske; Jörg Mütze; Karin Crell; Markus Landthaler; Petra Schwille
Journal:  Biophys J       Date:  2011-06-22       Impact factor: 4.033

7.  Synthesis and in vitro inhibition properties of siRNA conjugates carrying glucose and galactose with different presentations.

Authors:  Anna Aviñó; Sandra M Ocampo; Ricardo Lucas; José J Reina; Juan Carlos Morales; José Carlos Perales; Ramon Eritja
Journal:  Mol Divers       Date:  2011-01-26       Impact factor: 2.943

8.  Oxime ether lipids containing hydroxylated head groups are more superior siRNA delivery agents than their nonhydroxylated counterparts.

Authors:  Kshitij Gupta; Stephanie J Mattingly; Ralph J Knipp; Kirill A Afonin; Mathias Viard; Joseph T Bergman; Marissa Stepler; Michael H Nantz; Anu Puri; Bruce A Shapiro
Journal:  Nanomedicine (Lond)       Date:  2015-06-24       Impact factor: 5.307

9.  Sustained long-term RNA interference in nucleus pulposus cells in vivo mediated by unmodified small interfering RNA.

Authors:  Teppei Suzuki; Kotaro Nishida; Kenichiro Kakutani; Koichiro Maeno; Takashi Yurube; Toru Takada; Masahiro Kurosaka; Minoru Doita
Journal:  Eur Spine J       Date:  2009-01-14       Impact factor: 3.134

10.  Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology.

Authors:  Chun-Fang Xia; Yufeng Zhang; Yun Zhang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2007-10-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.